Taiwanese Bora Pharmaceuticals recently announced the establishment of Bora Biologics CDMO platform, and ready to invest $100M to acquire Eden Biologics’ CDMO assets, securing its leading position in Taiwan’s contract development and manufacturing organization (CDMO) market.
Acquisition of Eden’s CDMO facilities at Hsinchu Biomedical Science Park in Taiwan will jumpstart Bora Group’s first presence in the macromolecules, cell and gene therapy markets, a dramatic and significant shift from the company’s previous focus on small molecule drug manufacturing. With this buy, Bora will obtain cell lines development technologies for protein drugs manufacturing, upstream and downstream processes, quality control setups, etc., components crucial in widening its service offering.
Bora’s 5-Year CDMO Growth Project
The company has been diversifying rapidly over the past few years, with manufacturing sites set up on multiple continents. Just last month, Bora extended its Oral Solid Dose capabilities to a purpose-built site in Ontario, Canada, with funding for more than $10M over the next 2 years.
Seeking to reduce production costs, drug designers often arrange their manufacturing with CDMOs, for a reduction in costs connected to manufacturing, packaging, and testing, to improve gross margin while maintaining high product and manufacturing quality. In December 2021, the CDMO also acquired a GSK plant in Canada, symbolizing its first manufacturing footprint in Northern America.
Bora’s large share in the manufacturing field certainly will attract drug makers and therapeutics startups to do business with it while bolstering Taiwan’s position in the global pharmaceutical supply chain.
